Neos-King Pharma Inc.’s Post

I am pleased to share our latest publication in BMC Research Notes, where we examine the roles of galectin-3 and irisin as biomarkers in predicting severe COVID-19 outcomes. Galectin-3 emerged as a significant predictor, while irisin shows potential for future research. These findings may guide the development of targeted approaches for managing high-risk patients. Read more here:  https://lnkd.in/deDqyQv4  #COVID19 #Biomarkers #ClinicalResearch

Idiopathic pulmonary fibrosis (IPF) is a deadly disease with a poor prognosis, and a pressing need for improved therapies. Biomarkers have potential to improve clinical trials, and are essential tools for personalized patient management in IPF. In this blog, IQVIA’s Senior Medical Director and Strategy Lead Hassan Bencheqroun MD FCCP MBA, shares three key learnings on the potential role of biomarkers, based on IPF studies to date. https://bit.ly/3wNcRPs #biomarkers #clinicaltrials

Hello everyone, I’m thrilled to share our latest publication on exosomes and cardiomyopathies. Exosomes, small extracellular vesicles vital for intercellular communication, show great promise in diagnosing and treating cardiomyopathies. Their role in diseases like dilated, restrictive, arrhythmogenic, and hypertrophic cardiomyopathy highlights their potential as both diagnostic biomarkers and therapeutic targets. A deeper understanding of how exosomes affect disease progression could lead to better diagnosis and treatment strategies, ultimately improving patient outcomes. However, further research is needed to unlock their full clinical potential. Check out our Open Access article published in Life Science through the link below! #exosomes #cardiomyopathies #diagnosis #biomarkers #treatment

The microbiota pattern in young-onset and old-onset #colorectal_cancer appears to be similar. NOTES: - well-known CRC-associated taxa, such as #Clostridium_symbiosum, #Peptostreptococcus_stomatis, #Parvimonas_micra and #Hungatella_hathewayi were significantly enriched in both old- and young-onset patients. - Similar strain-level patterns of #Fusobacterium_nucleatum, #Bacteroides_fragilis and #Escherichia_coli were observed for oCRC and yCRC. - Almost all old CRC-associated metagenomic pathways had directionally concordant changes in young patients.

Stoked to see the first patient dosed in the Phase 3 MAGNITUDE Trial in US with NTLA-2001! NZCR, with Prof Ed Gane as Principal Investigator, was heavily involved in the Phase 1 study to get this CRISPR/Cas9 based gene editing drug tested for safety and efficacy in patients suffering from Heriditary Amyloidosis. As an investigator I was involved in treating many patients across Aotearoa and Australia with the one-off world-leading IV infusion that appears likely to be curative. NZCR is also participating in the MAGNITUDE trial, which means that patients in New Zealand will continue to have access to this drug during it's Phase 3 development. This is a really exciting space in biotechnology and drug development to be involved with as there are significant advancements! #NZ #Auckland #Aotearoa #NewZealand #clinicaltrials #clinicalresearch #amyloidosis #geneediting #CRISPR #medicine

NodThera’s NLRP3 inhibitor NT-0796 reverses neuroinflammation in Parkinson’s Disease phase Ib/IIa trial. The positive data from its Phase Ib/IIa study indicates that NT-0796 reduces key neuroinflammatory and inflammatory biomarkers in Parkinson’s disease patients to the levels found in healthy elderly controls over 28 days. The NLRP3 inflammasome is a main mediator of inflammation in many pathologies. NT-0796 selectively inhibits NLRP3, lowering levels of both pro-inflammatory cytokines IL-1β and IL-18. This action delivers therapeutic effects directly to immune cell types responsible for inflammatory diseases, including peripheral and neuroinflammatory diseases. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/ggT24Qr9   #Parkinson #Disease #clinical #Buildingblocks #NLRP3 #inflammasome #Inhibitor #brain #cytokine

#BCMA New insights are emerging in the fight against autoimmune diseases, with BCMA (B-cell maturation antigen) now in the spotlight. Traditionally associated with multiple myeloma treatment, BCMA is showing promise as a potential therapeutic target for autoimmune conditions like lupus and rheumatoid arthritis. This novel approach could pave the way for more effective treatments, reducing symptoms and improving quality of life for millions. Stay tuned as we follow the progress of this groundbreaking research! 🚀 https://lnkd.in/grJgRSBF #AutoimmuneDiseases #BCMA #Biotech #MedicalResearch #HealthcareInnovation

Alzheimer's disease diagnosis is on the brink of transformation with blood-based biomarker (BBM) tests. 🧠 🩸 Simpler, cheaper, and less invasive than current methods, blood biomarkers—detectable through a simple blood sample—are proving to be as sensitive as existing diagnostic tools, with accuracies above 90%. BBMs can be deployed in primary care, enhancing early diagnosis and reducing health disparities.  Lucent Diagnostics, part of Quanterix, is leading this revolution, partnering with global initiatives to implement BBMs in diverse settings. These advancements pave the way for accessible, easily administered tests, enabling early detection and better treatment outcomes. Read more ➡️

For clinical trials, certain exploratory outcomes can help discover important new insights into the effectiveness of the intervention, and to design subsequent trials. An interesting example is the COPDGene study (the largest #COPD study in the US involving more than 10,000 patients), for which Thirona has been running the quantitative image analysis for the entire main study. While COPD studies are generally focused on the development of emphysema and airways remodeling, we have additionally explored pulmonary vascular markers to investigate the involvement of the pulmonary arteries and veins in the development of COPD.  Learn more about the project: https://lnkd.in/ehs-icst

The first U.S. heart patient involved in a study for a new gene-editing therapy has successfully been treated at MedStar Washington Hospital Center. The pivotal Phase 3 MAGNITUDE clinical trial is evaluating the safety of a gene-editing treatment for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), an under-recognized cause of heart failure. Transthyretin amyloidosis is a protein disorder that typically affects the heart by stiffening the muscle and making it harder for the heart to pump blood throughout the body. The treatment is designed to prevent the production of an abnormal form of a protein called transthyretin that causes the disease. Learn more. https://bit.ly/4dpd0cA